Postoperative Nausea and Vomiting
Conditions
Brief summary
To assess the efficacy and safety of different doses of APD421 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystectomy (any surgical technique) or other elective surgery scheduled to last at least one hour from induction of anaesthesia), requiring at least one overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use for post-operative analgesia.
Interventions
DRUGAPD421
IV
DRUGPlacebo
IV
Sponsors
Acacia Pharma Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients ≥ 18 years of age 2. Ability and willingness to give written informed consent 3. Patients undergoing elective surgery under general anaesthesia requiring at least one overnight stay in hospital for either: 1. Hysterectomy (any surgical technique) 2. Cholecystectomy (any surgical technique) 3. Other elective surgery requiring overnight admission to hospital and scheduled to last at least 1 hour from induction of anaesthesia 4. Patients with at least 2 of the following risk factors for PONV: 1. Past history of PONV and/or motion sickness 2. Habitual non-smoking status 3. Female sex 4. Expected to receive opioid analgesia post-operatively 5. American Society of Anesthesiologists (ASA) risk score I-III 6. Adequate cardiac, hepatic and renal function * QTc interval \< 500 ms * Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \< 5 x upper limit normal (ULN) * Bilirubin \< 3 x ULN * Creatinine \< 2 x ULN 7. Adequate haematological function * Haemoglobin ≥ 9 g/dL * White blood count ≥ 3.0 x 109/L * Platelet count ≥ 100 x 109/L 8. For females of child-bearing potential: ability and willingness to use a highly effective form of contraception (e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner) or a double-barrier method of contraception such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom) between the date of screening and at least 48 hours after administration of study drug.
Exclusion criteria
1. Patients undergoing outpatient/day case surgery 2. Patients undergoing surgery where the patient is expected to remain ventilated for a period after surgery 3. Patients undergoing intra-thoracic, transplant or central nervous system surgery 4. Patients receiving a local anaesthetic/regional neuraxial (intrathecal or epidural) block 5. Patients who are expected to need a naso- or oral-gastric tube in situ after surgery is completed 6. Patients receiving the active ingredient of APD421 for any indication within the last 2 weeks 7. Patients who are allergic to the active ingredient or any of the excipients of APD421 8. Patients with a pre-existing vestibular disorder or history of dizziness 9. Patients with pre-existing nausea or vomiting in the 24 hours before surgery 10. Patients treated with regular anti-emetic therapy including corticosteroids 11. Patients being treated with medications which could induce torsades de pointes, including Class Ia antiarrhythmic agents such as quinidine, disopyramide, procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and other medications such as bepridil, cisapride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin 12. Patients being treated with levodopa 13. Patients who are pregnant or breast feeding 14. Patients with a history of alcohol abuse 15. Patients with pre-existing, clinically significant cardiac arrhythmia 16. Patients diagnosed with Parkinson's disease 17. Patients who have received anti-cancer chemotherapy in the previous 4 weeks 18. Patients with a history of epilepsy 19. Any other concurrent disease or illness that, in the opinion of the investigator makes the patient unsuitable for the study 20. Patients who have participated in a previous study within the last 28 days (French sites only: Patients who have participated in a previous study within the last 6 months, if required by national or local regulations)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post-operative Nausea or Vomiting | 24 hours |
Countries
France, Germany, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo | 54 |
| Low Dose APD421 1mg dose level | 58 |
| Mid Dose APD421 5mg dose level | 50 |
| High Dose APD421 20mg dose level | 53 |
| Total | 215 |
Baseline characteristics
| Characteristic | Placebo | Low Dose APD421 | Mid Dose APD421 | High Dose APD421 | Total |
|---|---|---|---|---|---|
| Age, Continuous | 49.1 years STANDARD_DEVIATION 13.6 | 50 years STANDARD_DEVIATION 14.5 | 50 years STANDARD_DEVIATION 16.2 | 50.7 years STANDARD_DEVIATION 15.7 | 49.9 years STANDARD_DEVIATION 14.9 |
| Sex: Female, Male Female | 47 Participants | 53 Participants | 48 Participants | 49 Participants | 197 Participants |
| Sex: Female, Male Male | 7 Participants | 5 Participants | 2 Participants | 4 Participants | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 52 / 54 | 50 / 58 | 39 / 50 | 46 / 53 |
| serious Total, serious adverse events | 2 / 54 | 1 / 58 | 0 / 50 | 2 / 53 |
Outcome results
Primary
Post-operative Nausea or Vomiting
Time frame: 24 hours
Population: ITT
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Post-operative Nausea or Vomiting | 37 participants |
| Low Dose APD421 | Post-operative Nausea or Vomiting | 28 participants |
| Mid Dose APD421 | Post-operative Nausea or Vomiting | 20 participants |
| High Dose APD421 | Post-operative Nausea or Vomiting | 30 participants |